EVALUATION AND MANAGEMENT OF RENAL TUMORS IN THE BIRT-HOGG-DUBÉ SYNDROME

DOI Web Site Web Site Web Site 12 Citations
  • CHRISTIAN P. PAVLOVICH
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • ROBERT L. GRUBB
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • KATHLEEN HURLEY
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • GLADYS M. GLENN
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • JORGE TORO
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • LAURA S. SCHMIDT
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • CARLOS TORRES-CABALA
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • MARIA J. MERINO
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • BERTON ZBAR
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • PETER CHOYKE
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • McCLELLAN M. WALTHER
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland
  • W. MARSTON LINEHAN
    From the Urologic Oncology (CP, RLG III, KH, MMW, MWL) and Genetic Epidemiology (GMG, JT) Branches, Division of Cancer Epidemiology and Genetics, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute Frederick (LSS), Frederick and Laboratories of Pathology (CT-C, MJM) and Immunobiology (BZ) and Molecular Imaging Program (PC), Center for Cancer Research, Bethesda, Maryland

Search this article

Journal

  • Journal of Urology

    Journal of Urology 173 (5), 1482-1486, 2005-05

    Ovid Technologies (Wolters Kluwer Health)

Citations (12)*help

See more

Report a problem

Back to top